EntryPoint Capital’s RxSight RXST Stock Holding History

EntryPoint Capital’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,315	Closed	-$101K	–	942
2026 Q1	$101K	Buy	+16,315	New	+$135K	0.03%	704
2025 Q4	–	Sell	-10,230	Closed	-$92K	–	835
2025 Q3	$92K	Buy	+10,230	New	+$89.8K	0.04%	628
2024 Q3	–	Sell	-1,675	Closed	-$101K	–	1234
2024 Q2	$101K	Buy	1,675 +1,132	+208%	+$64.7K	0.05%	819
2024 Q1	$28K	Sell	543 -294	-35%	-$14.4K	0.03%	981
2023 Q4	$33.7K	Buy	+837	New	+$24.6K	0.03%	886

Other funds holding RXST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.66B AUM 39.91% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EntryPoint Capital's RXST Position: Q2 2026 in Review

EntryPoint Capital sold out of RxSight (RXST) in Q2 2026, closing a stake of 16,315 shares — an estimated $101K sold.

EntryPoint Capital first reported a position in RXST in Q4 2023 and held it in 5 quarters. The position peaked at $101K in Q2 2024. 152 funds tracked by Wall St. Rank hold RXST as of Q2 2026.

EntryPoint Capital reported no remaining RxSight position as of Q2 2026 after selling out during the quarter.
EntryPoint Capital sold 16,315 RxSight shares in Q2 2026, an estimated $101K.
EntryPoint Capital first reported a position in RxSight in Q4 2023 and held it in 5 quarters.
EntryPoint Capital's RxSight position peaked at $101K in Q2 2024.
152 funds tracked by Wall St. Rank held RxSight as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.